Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Immune Therapeutics Inc. (IMUN)

Add IMUN Price Alert      Hide Sticky   Hide Intro
Moderator: crudeoil24, The Rainmaker, JDoggs_Money, dwarren428
Search This Board: 
Last Post: 7/27/2017 11:41:16 PM - Followers: 76 - Board type: Free - Posts Today: 0

IMUN - Immune Therapeutics

Contact Info

  • 37 North Orange Ave
    Suite 607
    Orlando, FL 32801
Shareholders of Record 773     a/o Mar 31, 2017
Short Selling Data
Short Interest 22,499 (-87.71%)
Jun 30, 2017
Significant Failures to Deliver No

  Authorized Shares 500,000,000 a/o July 17, 2017
  Outstanding Shares 334,037,491 a/o July 17, 2017

Quick Links: (subsidiary of IMUN - Cytocom will get eventual U.S. sales - if that ever happens - hopefully in 2-3 years?? IMUN owns 13.3% of Cytocom as of March 31, 2017. LDN has already received various Phase 2 approvals in the United States, see (partner in Nigeria for marketing and distribution - potentially also for manufacturing in the future? See their newly built plant) (partner for manufacturing in Dominican Republic - contract in 8-k)

Important Links:

8-k from 4/27/16: LDN is approved in Nigeria

8-k from 11/2/16: Contract with IMUN's manufacturer in the Domincan Republic, Acromax Dominicana

8-k from 4/13/17: Debt restructuring to eliminate a very "toxic" note. This 8-k may have marked the inflection point on the graph of IMUN

8-k from 4/28/17: IMUN files NDA for LDN for HIV and Cancer in Kenya 

8-k from 5/23/17: LDN gets marketing approval in Nigeria

PR from 5/31/17: IMUN signs MoU with Ivory Coast for LDN

PR from 10/26/16: IMUN files NDA for LDN for HIV, Cancer and as an Immune Booster with Senegal

PR from August 2015: Letter of Intent from Fidson Healthcare PLC - this publishing popped IMUN to just over $0.30 briefly

Stock Quote of Fidson Healthcare PLC - IMUN's partner for marketing / distribution in Nigeria - notice how the ticker has shot up since April on no published news (According to Bloomberg), could also have something to do with new plant they built

8-k from 4/13/16: IMUN Provides Drug Development Status on MENK (Methionine-Enkelphine) in China

8-k from 4/21/16: IMUN signs binding LOI to acquire Chinese CAR-T Technology and Clinical data

Nigeria Clinical Trials Registry - Lodonal - note that it still says "Pending". According to 8-k's, the drug is officially approved, so IMUN should be good on this 

Low Dose Naltrexone Forum - Proboards

LDN Clinical Trials via (has not been updated since 2013, but still a very nice list)

List of Clinical Trial Publications for LDN via

11 Facts about HIV in Africa

The medicine your doctor never told you about (but should have)

Low-Dose Naltrexone (LDN): One of the RARE Drugs that Actually Helps Your Body to Heal Itself

My experience with Low Dose Naltrexone By David Gluck, MD (the story of a lifelong friend of Dr. Bernard Bihari, the pioneer of LDN)

We now have a NEW Senior Regulatory Advisor (see last page of powerpoint) who is (or was?) ALSO the Senior Regulatory Officer for the GATES FOUNDATION!  - other than the powerpoint presentation from the LD Micro conference, there has not yet been any 8-k recognizing any of these new additions (Dr. John H Abeles, Rufus (Rudy) Williams, Vincent Ahonkhai). 

Videos to watch on Low Dose Naltrexone (4 mins, CBS News - Wonder drug Low Dose Naltrexone?...very uplifting encouraging video about a woman's story on LDN) 

In this 4 min video above, it states that no Big Pharma companies are backing LDN. This is correct, because it is off-label: 50-mg Naltrexone was approved by the FDA in the 80's. Thus, making it cheap because 50-mg Naltrexone is generic (50mg Naltrexone didn't work well for what it was approved for - heroin addicts, therefore it ended up becoming generic). Low dose naltrexone, 4.5mg, however, is patented, and studies have shown its effectiveness (44% increase in CD4 count in Nigerian trials, when they were searching for a minimum of 25% increase in CD4 count). And it's safe - very little side effects except for possible lucid dreams. But still, it's "cheap". Noreen says it will costs patients in Nigeria $.84 per day, $0.24 of which will be profit. The low cost is the reason why big pharma did not WANT to fund this drug. Because there has always been little research done on LDN, big pharma was happy keeping it that way. They knew that if LDN did ever gain traction as the go-to therapy for any given disease, it would make big pharma lose billions of dollars, if in fact LDN can replace more expensive drugs that the big pharma companies are selling. This could potentially make IMUN a potential acquisition target by big pharma in the future. (59 mins; very informative documentary telling the story of LDN) [11 mins; a woman gives a detailed explanation of how LDN has helped her - 4 month update (not doing so well) and 1 year update (doing much better)] (79 mins; "[the late] Dr Bihari [the pioneer of low dose naltrexone] is Interviewed about Low Dose Naltrexone LDN for Normalizing Immune System Function") (60 mins; LDN & Cancer - The Game Changer) (29 mins; LDN as a treatment for Autoimmune disease)

Books on Low Dose Naltrexone (great reviews on Amazon)

Upcoming Catalysts (expected)
-From May 23rd 8-k: "Initial contracts expected shortly". IMUN will be reporting contracts with Fidson Healthcare PLC (hopefully), as well as organizations that will help with the funding of purchase orders (still unclear what is exactly the deal?) - from the June 12th Powerpoint 8-k, "Collaboration NGO, Foundation, PEPFAR, PATH, NACA, NCA, HMO, GATES LOCAL DISTRIBUTION".

-From May 23rd 8-k: "Company expected to strengthen management team". Note that on the June 12th 8-k, on the final page, there was mention of three new officers / advisors in Dr. John H. Abeles, Rufus (Rudy) Williams, and Dr. Vincent Ahonkhai (senior regulatory officer for the Gates Foundation). As we haven't seen a specific 8-k regarding these new additions (have only seen this Powerpoint which is likely not official), it appears as if there should still be a separate announcement in an 8-k.

-From June 12th 8-k: "Sales [in Nigeria] by end of Q3 2017", as well as "AHAR Pharma LTD Nigeria - Telemedicine operational by July 2017", from "Lodonal - Commericialization Steps" Powerpoint slide.

-From April 28th 8-k: “The [NDA for Kenya] was accepted and the company has received an application number. From there, we will move through the regulatory approval process including manufacturing (GMP) assessment, National Quality Control laboratory analysis, regulatory committee review and committee recommendations before the board issues its final ruling. The approval process could take as little as 90 days, after which we will be prepared to take orders for shipment through our recently announced distributi on agreement.” concluded Griffin. The Company plans to reach commercialization for Lodonal in Kenya in 2017.


Patent and Subsidiary Acquisition (from the 10-k)

The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000.

  • "Cytocom. Cytocom Inc. is our affiliate clinical-stage pharmaceutical company focused on advancing IRT-103 (US FDA designator for ‘Lodonal’). It is responsible for the development of our patented therapies with the FDA and EMA. It will lead the US and EMA (“European Medical Association”) clinical trials on IRT-103 including for Crohn’s disease. We have quietly made solid progress advancing Cytocom toward our next major goal, which is to finance it as a standalone entity, possibly publicly traded depending on its capital market valuation and profile."

    The following link contains an important Powerpoint presentation. Page 8 of the presentation is a key page. As of March 31, 2017, IMUN owns a 13.3% stake in Cytocom, which has been diluted down from an original 55% stake when the spinoff occured in 2014.
  • "Advance IMUN’s Growing Drug Pipeline. We have started our second clinical for Lodonal as an adjunct treatment for cancer in Malawi, which is slated for completion in mid-2017, with results to be published in the second half of the year. We also plan a bridging trial with MENK for cancer in Nigeria, capitalizing on our strong relationship with NAFDAC -– amongst other clinical trials being developed or planned.

    Increase the IP Portfolio. We will continue to protect the value of our clinical research by building intellectual property value as an asset, thus erecting barriers to entry. We filed two new patents surrounding Lodonal in 2016.
    Establish a Solid Base of Operations in China. Our Chief Science Officer and Vice Director of the Institute of Immunology, China Medical University in Shenyang, China have been treating patients with MENK and our new cocktail therapy throughout 2016 with positive results. Now that our patents are filed for the cocktail, we plan to publish results in 2017 as part of a larger initiative to advance clinical trials, and establish a solid beachhead in this nation of 1.4 billion people as a gateway to Asia.  Our goal is to open our cancer clinic in China to treat patients by year-end 2017.
    Reinforce the IMUN Management Team and Boards. As we grow, and our opportunities increase, we plan to add highly accomplished executives to our management team and boards from the fields of science, medicine, pharmaceuticals and finance to help drive the Company’s growth."

***The following Powerpoint is copy and pasted from the June 12th 8-k. It was presented at the LD Micro Conference on June 7th***

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMUN News: Current Report Filing (8-k) 06/12/2017 06:04:21 AM
IMUN News: Current Report Filing (8-k) 05/23/2017 11:12:57 AM
IMUN News: Quarterly Report (10-q) 05/12/2017 12:32:57 PM
IMUN News: Current Report Filing (8-k) 05/09/2017 06:09:05 AM
IMUN News: Current Report Filing (8-k) 04/28/2017 03:57:12 PM
#3263  Sticky Note I want to say something about this "Marshall dwarren428 07/25/17 03:47:23 PM
#2953  Sticky Note Gates Foundation money is a big deal here. crudeoil24 06/09/17 09:01:10 AM
#2366  Sticky Note IMUN: The CEO gave Lodonol contract numbers during The Rainmaker 04/15/17 02:01:35 PM
#2316  Sticky Note Here’s my DD for $IMUN: JDoggs_Money 04/13/17 10:26:58 PM
#3277 has just been added to the IBox. This dwarren428 07/27/17 11:41:16 PM
#3276   If the dump and pump appears ineffective and dwarren428 07/27/17 10:26:40 AM
#3275   I know I've responded to this before, but dwarren428 07/26/17 03:13:49 PM
#3274   ok, Thanks. tjguy 07/26/17 02:42:02 PM
#3273   Fidson Healthcare PLC, IMUN's partner for marketing and dwarren428 07/26/17 12:12:30 PM
#3272   Low Dose Naltrexone Forum - Proboards dwarren428 07/26/17 11:43:18 AM
#3271   And of course...the best way to get answers dwarren428 07/26/17 11:39:50 AM
#3270   And some more info here... dwarren428 07/26/17 10:24:57 AM
#3269   And from the Nigerian Bridging Trial in 2016... dwarren428 07/26/17 10:09:04 AM
#3268   For HIV/AIDS, it can be used as a dwarren428 07/26/17 09:50:10 AM
#3267   If this drug works, it's a no brainer. tjguy 07/26/17 09:25:31 AM
#3266   Africa. Still the largest population of aids caseS. Hopeful1037 07/25/17 05:13:18 PM
#3264   I had to post that again, because I dwarren428 07/25/17 03:48:09 PM
#3263   I want to say something about this "Marshall dwarren428 07/25/17 03:47:23 PM
#3262   Oh, right. That would be great! tjguy 07/25/17 11:45:14 AM
#3261   I was thinking Nigeria contracts with Kenya approval. Herold 07/25/17 11:36:54 AM
#3260   That would be nice, but they did not tjguy 07/25/17 11:32:27 AM
#3259   They should announce Kenya approval and contracts at Herold 07/25/17 11:30:57 AM
#3258   Any good news would be appreciated at this Lapbid 07/25/17 11:02:14 AM
#3257   We could possibly hear a ruling on their tjguy 07/25/17 01:57:00 AM
#3256   I know I've said a lot of that dwarren428 07/25/17 12:35:10 AM
#3251   I'm trying to do a little detective work dwarren428 07/24/17 10:05:25 PM
#3249   This has just been added to the IBOX. dwarren428 07/24/17 04:09:42 AM
#3248   In my opinion (and yes of course I dwarren428 07/23/17 12:27:44 AM
#3245   One has to believe the truth. It's taken Hopeful1037 07/22/17 08:26:04 PM
#3243   Investment Philosophy - don't dwarren428 07/22/17 06:30:14 PM
#3236   Bootysweat, question for you: dwarren428 07/22/17 12:20:48 PM
#3232   SSDBase, question for you: dwarren428 07/22/17 12:07:46 PM
#3230   4thKing, question for you: dwarren428 07/22/17 11:58:40 AM
#3229   JSMill, question for you: dwarren428 07/22/17 11:52:23 AM
#3228   Rock Kicker, question for you: dwarren428 07/22/17 11:42:25 AM
#3227   Bababooyah, question for you: dwarren428 07/22/17 11:39:29 AM
#3226   If you don't think this stock has been dwarren428 07/22/17 11:28:26 AM
#3225   The 10 q is due in mid Aug. Lapbid 07/22/17 10:51:17 AM
#3224   The Dump & Pump thing doesn't sit right tjguy 07/22/17 08:25:49 AM
#3223   I don't know what the hell is going dwarren428 07/21/17 02:46:26 PM
#3222   If this stock is "Dump and Pump", as dwarren428 07/21/17 12:17:16 PM
#3221   That is what is discouraging. The CEO shouldnt bpammy 07/21/17 12:03:38 PM
#3220   Yea, that's what I want to know. I've dwarren428 07/21/17 10:46:30 AM
#3219   Coming weeks....30 days.....ok where are the contracts? Lapbid 07/21/17 10:44:19 AM
#3218   I don't think it ever said 30 days dwarren428 07/21/17 10:38:45 AM
#3217   I dont remember where i read 30 days, Lapbid 07/21/17 10:34:27 AM
#3216   Over 800k volume in the first hour of dwarren428 07/21/17 10:28:22 AM
#3215   When did she say that? PowerPoint says sales dwarren428 07/21/17 10:23:39 AM
#3214   5/23/17 was the date for the authorisation to Lapbid 07/21/17 10:14:51 AM
#3213   Bid and ask seem to keep on dropping tjguy 07/21/17 08:33:55 AM
#3210   Got my order in for a penny bababooyah 07/20/17 03:02:11 PM
#3209   I tend to agree with you regarding the Lapbid 07/20/17 02:37:42 PM
#3208   I understand the desire to increase the investor Sackofsasquatch 07/19/17 08:00:23 PM
#3207   I'm not hoping for a short term flip dwarren428 07/19/17 05:26:17 PM